Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Vivus begins patient enrollment for female sexual dysfunction trial

Oct. 30, 2000

Pamidronate improves osteoporosis following lung transplant in cystic fibrosis patients

Oct. 27, 2000

Gaucher's disease therapy receives European orphan drug status

Oct. 26, 2000

Preparation and use of protease inhibitor series particularly useful in bone diseases

Oct. 26, 2000

U.S. patent covers new series of GH secretagogues from Novo Nordisk

Oct. 26, 2000

Novel meiosis inhibitors emerge from Akzo Nobel R&D

Oct. 24, 2000

Recent patent covers Medicure's new pyridoxal analogues

Oct. 24, 2000

U. of Mississippi prepares novel series of PPARgamma-activating agents

Oct. 24, 2000

New Y5 receptor antagonists claimed for eating disorders, etc. by Synaptic

Oct. 24, 2000

Once-weekly Fosamax approved by FDA

Oct. 24, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...